Quick Answer
Akebia Therapeutics, Inc. reported Total Assets of $376.57 million for the year ending 2025.
- Akebia Therapeutics, Inc. showed an increase of +70.6% in Total Assets from 2024 to 2025.
- This data is from Akebia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $134.03 million | Q2 2014: $126.36 million | Q3 2014: $120.17 million | Q1 2015: $103.46 million | Q2 2015: $155.67 million | Q3 2015: $159.59 million | Q1 2016: $221.44 million | Q2 2016: $195.64 million | Q3 2016: $169.12 million | Q1 2017: $259.26 million | Q2 2017: $336.82 million | Q3 2017: $338.59 million | Q1 2018: $442.71 million | Q2 2018: $413.78 million | Q3 2018: $403.83 million | Q1 2019: $890.79 million | Q2 2019: $823.53 million | Q3 2019: $795.22 million | Q1 2020: $787.72 million | Q2 2020: $745.17 million | Q3 2020: $676.14 million | Q1 2021: $628.70 million | Q2 2021: $611.86 million | Q3 2021: $602.27 million | Q1 2022: $541.80 million | Q2 2022: $529.88 million | Q3 2022: $435.89 million | Q1 2023: $280.93 million | Q2 2023: $253.71 million | Q3 2023: $235.00 million | Q1 2024: $225.48 million | Q2 2024: $220.20 million | Q3 2024: $207.14 million | Q1 2025: $310.19 million | Q2 2025: $345.60 million | Q3 2025: $364.15 million.
- Over the full 13 years of available data (2013 to 2025), Akebia Therapeutics, Inc.'s Total Assets has grown by 986.3%.
- Historical annual values: Fiscal year 2025: $376.57 million | Fiscal year 2024: $220.67 million | Fiscal year 2023: $241.70 million | Fiscal year 2022: $356.05 million | Fiscal year 2021: $525.55 million | Fiscal year 2020: $644.14 million | Fiscal year 2019: $771.20 million | Fiscal year 2018: $996.54 million | Fiscal year 2017: $364.25 million | Fiscal year 2016: $300.22 million | Fiscal year 2015: $142.94 million | Fiscal year 2014: $111.00 million | Fiscal year 2013: $34.67 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: